| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 294 | 2024 | 5740 | 16.600 |
Why?
|
| Proto-Oncogene Proteins B-raf | 165 | 2024 | 2072 | 13.750 |
Why?
|
| Protein Kinase Inhibitors | 119 | 2025 | 5709 | 6.150 |
Why?
|
| Pyrimidinones | 41 | 2024 | 387 | 5.750 |
Why?
|
| Skin Neoplasms | 109 | 2024 | 5891 | 5.140 |
Why?
|
| Antineoplastic Agents | 123 | 2024 | 13708 | 4.870 |
Why?
|
| Pyridones | 40 | 2024 | 819 | 4.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 85 | 2024 | 11843 | 4.220 |
Why?
|
| Oximes | 35 | 2022 | 304 | 4.150 |
Why?
|
| Indoles | 57 | 2024 | 1834 | 3.950 |
Why?
|
| Sulfonamides | 60 | 2024 | 1988 | 3.950 |
Why?
|
| Imidazoles | 42 | 2022 | 1174 | 3.450 |
Why?
|
| Drug Resistance, Neoplasm | 79 | 2024 | 5342 | 3.330 |
Why?
|
| Mutation | 114 | 2024 | 30243 | 2.970 |
Why?
|
| Benzenesulfonates | 21 | 2013 | 166 | 2.910 |
Why?
|
| Molecular Targeted Therapy | 46 | 2024 | 2834 | 2.880 |
Why?
|
| Neoplasms | 69 | 2025 | 22386 | 2.840 |
Why?
|
| Benzimidazoles | 17 | 2024 | 864 | 2.730 |
Why?
|
| Carbamates | 7 | 2024 | 192 | 2.170 |
Why?
|
| MAP Kinase Signaling System | 30 | 2018 | 1489 | 2.170 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 24 | 2023 | 639 | 2.120 |
Why?
|
| Pyridines | 31 | 2025 | 2888 | 2.100 |
Why?
|
| Phenylurea Compounds | 33 | 2019 | 532 | 2.050 |
Why?
|
| Immunotherapy | 38 | 2023 | 4728 | 1.870 |
Why?
|
| Carcinoma, Renal Cell | 28 | 2021 | 3197 | 1.810 |
Why?
|
| Mitogen-Activated Protein Kinases | 21 | 2022 | 1246 | 1.720 |
Why?
|
| Niacinamide | 31 | 2017 | 419 | 1.650 |
Why?
|
| Kidney Neoplasms | 27 | 2021 | 4298 | 1.600 |
Why?
|
| Quinoxalines | 2 | 2024 | 297 | 1.570 |
Why?
|
| Piperazines | 14 | 2025 | 2546 | 1.420 |
Why?
|
| GTP Phosphohydrolases | 10 | 2024 | 525 | 1.380 |
Why?
|
| MAP Kinase Kinase Kinases | 11 | 2020 | 252 | 1.340 |
Why?
|
| Neoplasm Metastasis | 44 | 2024 | 4931 | 1.290 |
Why?
|
| MAP Kinase Kinase 1 | 11 | 2020 | 333 | 1.280 |
Why?
|
| Pyrazoles | 4 | 2024 | 2024 | 1.280 |
Why?
|
| Proto-Oncogene Proteins c-kit | 12 | 2024 | 727 | 1.260 |
Why?
|
| National Cancer Institute (U.S.) | 8 | 2024 | 300 | 1.250 |
Why?
|
| Cyclin-Dependent Kinase 4 | 7 | 2025 | 564 | 1.220 |
Why?
|
| Humans | 439 | 2025 | 768451 | 1.200 |
Why?
|
| Clinical Trials as Topic | 33 | 2024 | 8051 | 1.190 |
Why?
|
| Disease-Free Survival | 39 | 2021 | 6856 | 1.030 |
Why?
|
| Gene Amplification | 8 | 2025 | 1091 | 1.030 |
Why?
|
| Cell Line, Tumor | 89 | 2024 | 17149 | 1.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2025 | 352 | 1.000 |
Why?
|
| Receptor, erbB-2 | 6 | 2024 | 2586 | 0.990 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 8 | 2019 | 258 | 0.990 |
Why?
|
| Signal Transduction | 58 | 2020 | 23638 | 0.930 |
Why?
|
| Neurofibromin 2 | 2 | 2024 | 272 | 0.900 |
Why?
|
| MAP Kinase Kinase 2 | 5 | 2020 | 93 | 0.900 |
Why?
|
| Middle Aged | 145 | 2025 | 223418 | 0.880 |
Why?
|
| Aged, 80 and over | 69 | 2025 | 59680 | 0.850 |
Why?
|
| Xenograft Model Antitumor Assays | 32 | 2024 | 3619 | 0.840 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 8 | 2019 | 665 | 0.830 |
Why?
|
| Immunologic Factors | 6 | 2020 | 1600 | 0.830 |
Why?
|
| Maximum Tolerated Dose | 12 | 2019 | 890 | 0.820 |
Why?
|
| Quinazolines | 8 | 2022 | 1376 | 0.810 |
Why?
|
| Benzamides | 8 | 2024 | 1381 | 0.810 |
Why?
|
| Aged | 121 | 2025 | 171520 | 0.810 |
Why?
|
| Pyrimidines | 10 | 2024 | 3050 | 0.800 |
Why?
|
| Acrylamides | 1 | 2024 | 260 | 0.800 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2024 | 3665 | 0.780 |
Why?
|
| Aniline Compounds | 3 | 2024 | 1094 | 0.780 |
Why?
|
| Periodicals as Topic | 8 | 2022 | 1468 | 0.760 |
Why?
|
| Antibodies, Monoclonal | 25 | 2021 | 9263 | 0.750 |
Why?
|
| Female | 184 | 2025 | 396943 | 0.740 |
Why?
|
| Drug Discovery | 4 | 2017 | 1062 | 0.740 |
Why?
|
| Ameloblastoma | 1 | 2021 | 42 | 0.720 |
Why?
|
| Codon | 4 | 2021 | 599 | 0.720 |
Why?
|
| Jaw Neoplasms | 1 | 2021 | 72 | 0.710 |
Why?
|
| Neutropenia | 5 | 2023 | 892 | 0.710 |
Why?
|
| Breast Neoplasms | 8 | 2024 | 21156 | 0.700 |
Why?
|
| Adult | 114 | 2025 | 223542 | 0.690 |
Why?
|
| Drug Eruptions | 4 | 2018 | 335 | 0.690 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2024 | 342 | 0.680 |
Why?
|
| Pyrroles | 8 | 2021 | 1127 | 0.680 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 11 | 2016 | 617 | 0.680 |
Why?
|
| Apoptosis | 35 | 2021 | 9526 | 0.670 |
Why?
|
| Phosphatidylinositol 3-Kinases | 11 | 2022 | 2884 | 0.670 |
Why?
|
| Genes, ras | 10 | 2019 | 666 | 0.660 |
Why?
|
| Gene Expression Regulation, Neoplastic | 35 | 2024 | 8635 | 0.660 |
Why?
|
| Male | 163 | 2025 | 364781 | 0.660 |
Why?
|
| Uveal Neoplasms | 6 | 2019 | 344 | 0.640 |
Why?
|
| Membrane Proteins | 12 | 2021 | 7895 | 0.620 |
Why?
|
| Neoplasm Staging | 36 | 2021 | 11249 | 0.600 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2022 | 2964 | 0.600 |
Why?
|
| Deoxycytidine | 6 | 2020 | 888 | 0.600 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 808 | 0.600 |
Why?
|
| Neurofibromatosis 1 | 1 | 2023 | 561 | 0.590 |
Why?
|
| Carboplatin | 8 | 2015 | 798 | 0.590 |
Why?
|
| Paclitaxel | 12 | 2020 | 1737 | 0.590 |
Why?
|
| Brain Neoplasms | 15 | 2024 | 9182 | 0.580 |
Why?
|
| Neoplasm Proteins | 12 | 2018 | 3611 | 0.570 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 249 | 0.560 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 4642 | 0.550 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2014 | 664 | 0.550 |
Why?
|
| Animals | 108 | 2024 | 169418 | 0.530 |
Why?
|
| Triazoles | 3 | 2018 | 905 | 0.530 |
Why?
|
| Indazoles | 1 | 2018 | 306 | 0.520 |
Why?
|
| Pyrrolidines | 1 | 2018 | 341 | 0.520 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2024 | 1614 | 0.510 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2024 | 259 | 0.510 |
Why?
|
| Treatment Outcome | 59 | 2025 | 65409 | 0.510 |
Why?
|
| Congresses as Topic | 4 | 2020 | 810 | 0.500 |
Why?
|
| Dacarbazine | 9 | 2020 | 560 | 0.490 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 1362 | 0.490 |
Why?
|
| Disease Progression | 30 | 2022 | 13655 | 0.480 |
Why?
|
| Pyrazines | 2 | 2024 | 1206 | 0.480 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2021 | 720 | 0.460 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2014 | 63 | 0.460 |
Why?
|
| Young Adult | 38 | 2024 | 60045 | 0.450 |
Why?
|
| Melanocytes | 7 | 2021 | 512 | 0.450 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 2019 | 3520 | 0.450 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 4 | 2024 | 109 | 0.450 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2015 | 355 | 0.440 |
Why?
|
| Tumor Microenvironment | 13 | 2023 | 3939 | 0.440 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 614 | 0.430 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2024 | 196 | 0.430 |
Why?
|
| Interferon-gamma | 4 | 2023 | 3169 | 0.430 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2020 | 637 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 21 | 2019 | 6537 | 0.420 |
Why?
|
| Mice | 74 | 2024 | 82045 | 0.420 |
Why?
|
| Prognosis | 41 | 2021 | 30028 | 0.420 |
Why?
|
| Colorectal Neoplasms | 5 | 2021 | 6978 | 0.410 |
Why?
|
| Drug Delivery Systems | 8 | 2017 | 2238 | 0.410 |
Why?
|
| src-Family Kinases | 1 | 2015 | 539 | 0.400 |
Why?
|
| Survival Rate | 22 | 2021 | 12875 | 0.390 |
Why?
|
| Alleles | 3 | 2022 | 6890 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-raf | 7 | 2017 | 205 | 0.380 |
Why?
|
| United States Food and Drug Administration | 6 | 2021 | 1669 | 0.370 |
Why?
|
| Nausea | 6 | 2022 | 682 | 0.370 |
Why?
|
| Research Design | 8 | 2024 | 6217 | 0.370 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2021 | 3550 | 0.370 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 13589 | 0.360 |
Why?
|
| Mice, Nude | 18 | 2024 | 3635 | 0.360 |
Why?
|
| Angiogenesis Inhibitors | 9 | 2013 | 2062 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-akt | 11 | 2021 | 2465 | 0.360 |
Why?
|
| Lymphoma | 1 | 2020 | 1907 | 0.350 |
Why?
|
| Azetidines | 6 | 2021 | 143 | 0.350 |
Why?
|
| Cell Proliferation | 23 | 2024 | 10494 | 0.340 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2021 | 200 | 0.340 |
Why?
|
| Phosphoproteins | 3 | 2015 | 2450 | 0.340 |
Why?
|
| United States | 25 | 2024 | 73121 | 0.330 |
Why?
|
| Interferons | 3 | 2022 | 714 | 0.330 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 906 | 0.330 |
Why?
|
| Fever | 5 | 2021 | 1622 | 0.330 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 6320 | 0.330 |
Why?
|
| Drug Design | 3 | 2013 | 1050 | 0.330 |
Why?
|
| Administration, Oral | 12 | 2019 | 4041 | 0.320 |
Why?
|
| Drug Administration Schedule | 15 | 2019 | 4861 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5426 | 0.310 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2022 | 4083 | 0.310 |
Why?
|
| ras Proteins | 6 | 2016 | 1058 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-myc | 5 | 2017 | 998 | 0.310 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2011 | 423 | 0.310 |
Why?
|
| Cyclin D1 | 4 | 2023 | 454 | 0.300 |
Why?
|
| Enzyme Inhibitors | 8 | 2024 | 3734 | 0.300 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1766 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2018 | 10784 | 0.300 |
Why?
|
| Isoenzymes | 2 | 2011 | 1685 | 0.300 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 8559 | 0.290 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2015 | 2910 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2018 | 474 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2019 | 1409 | 0.280 |
Why?
|
| Diarrhea | 4 | 2022 | 1320 | 0.270 |
Why?
|
| Genomics | 5 | 2024 | 5909 | 0.270 |
Why?
|
| Piperidines | 8 | 2021 | 1664 | 0.270 |
Why?
|
| TOR Serine-Threonine Kinases | 8 | 2017 | 2067 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2022 | 10358 | 0.270 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2022 | 876 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2018 | 478 | 0.260 |
Why?
|
| Nephrectomy | 3 | 2021 | 949 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2021 | 9425 | 0.260 |
Why?
|
| Time Factors | 23 | 2022 | 40271 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 13 | 2021 | 6135 | 0.260 |
Why?
|
| Double-Blind Method | 13 | 2021 | 12450 | 0.250 |
Why?
|
| Survival Analysis | 16 | 2024 | 10125 | 0.250 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 2010 | 0.250 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 718 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 4 | 2017 | 2643 | 0.240 |
Why?
|
| raf Kinases | 3 | 2015 | 118 | 0.240 |
Why?
|
| Tamoxifen | 3 | 2015 | 968 | 0.240 |
Why?
|
| Receptor, EphA2 | 2 | 2014 | 41 | 0.240 |
Why?
|
| Mice, SCID | 10 | 2021 | 2633 | 0.230 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 2243 | 0.230 |
Why?
|
| Biopsy | 6 | 2020 | 6816 | 0.230 |
Why?
|
| Ploidies | 1 | 2024 | 287 | 0.230 |
Why?
|
| Quality of Life | 4 | 2021 | 13497 | 0.230 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2023 | 148 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 1062 | 0.230 |
Why?
|
| Area Under Curve | 6 | 2012 | 1640 | 0.230 |
Why?
|
| Melanoma, Experimental | 4 | 2015 | 561 | 0.220 |
Why?
|
| Cell Cycle | 8 | 2019 | 2942 | 0.220 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2014 | 2882 | 0.220 |
Why?
|
| Medical Oncology | 6 | 2023 | 2347 | 0.220 |
Why?
|
| DNA Mutational Analysis | 9 | 2016 | 4120 | 0.220 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2023 | 199 | 0.220 |
Why?
|
| Membrane Glycoproteins | 4 | 2019 | 3713 | 0.210 |
Why?
|
| Aminopyridines | 2 | 2017 | 578 | 0.210 |
Why?
|
| Patient Selection | 5 | 2019 | 4266 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2016 | 1119 | 0.210 |
Why?
|
| Antibodies, Catalytic | 1 | 2022 | 1 | 0.210 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2018 | 1628 | 0.200 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2015 | 330 | 0.200 |
Why?
|
| Thionucleosides | 2 | 2021 | 13 | 0.200 |
Why?
|
| Neural Stem Cells | 2 | 2021 | 892 | 0.200 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 408 | 0.200 |
Why?
|
| bcl-X Protein | 1 | 2024 | 412 | 0.200 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2023 | 103 | 0.200 |
Why?
|
| Tumor Escape | 4 | 2020 | 374 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2017 | 1104 | 0.200 |
Why?
|
| Piperidones | 1 | 2022 | 37 | 0.200 |
Why?
|
| Oxazepines | 1 | 2022 | 22 | 0.200 |
Why?
|
| Deoxyguanosine | 2 | 2021 | 96 | 0.190 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 57 | 0.190 |
Why?
|
| Interferon-alpha | 4 | 2016 | 909 | 0.190 |
Why?
|
| Biomedical Research | 6 | 2021 | 3463 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2017 | 1536 | 0.190 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2021 | 78 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 2254 | 0.190 |
Why?
|
| Estradiol | 2 | 2017 | 1949 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2021 | 68 | 0.180 |
Why?
|
| Government Agencies | 1 | 2021 | 161 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 4 | 2020 | 2896 | 0.180 |
Why?
|
| Acetates | 1 | 2022 | 318 | 0.180 |
Why?
|
| Lamins | 1 | 2020 | 37 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2018 | 4534 | 0.180 |
Why?
|
| Coenzyme A Ligases | 1 | 2020 | 45 | 0.180 |
Why?
|
| Enzyme Activation | 6 | 2017 | 3594 | 0.170 |
Why?
|
| Glucocorticoids | 2 | 2021 | 2170 | 0.170 |
Why?
|
| Follow-Up Studies | 20 | 2021 | 39430 | 0.170 |
Why?
|
| Ki-67 Antigen | 2 | 2016 | 631 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 679 | 0.170 |
Why?
|
| Glioblastoma | 3 | 2024 | 3523 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 4 | 2019 | 940 | 0.170 |
Why?
|
| Intention to Treat Analysis | 4 | 2015 | 417 | 0.170 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2019 | 53 | 0.170 |
Why?
|
| Oxazoles | 1 | 2021 | 199 | 0.170 |
Why?
|
| Phenotype | 10 | 2018 | 16712 | 0.170 |
Why?
|
| Mice, Inbred NOD | 6 | 2021 | 1839 | 0.160 |
Why?
|
| Lamin Type A | 1 | 2020 | 189 | 0.160 |
Why?
|
| Drug Synergism | 3 | 2019 | 1765 | 0.160 |
Why?
|
| B-Lymphocytes | 3 | 2021 | 4781 | 0.160 |
Why?
|
| Immune Evasion | 1 | 2023 | 377 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 958 | 0.160 |
Why?
|
| Biological Availability | 2 | 2018 | 390 | 0.160 |
Why?
|
| Sirolimus | 4 | 2015 | 1542 | 0.160 |
Why?
|
| Neural Crest | 1 | 2021 | 279 | 0.160 |
Why?
|
| Antacids | 1 | 2019 | 94 | 0.160 |
Why?
|
| Spheroids, Cellular | 6 | 2023 | 332 | 0.160 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2022 | 733 | 0.160 |
Why?
|
| Academies and Institutes | 1 | 2021 | 326 | 0.160 |
Why?
|
| Retinoid X Receptor gamma | 1 | 2018 | 3 | 0.160 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 2 | 2016 | 85 | 0.160 |
Why?
|
| POU Domain Factors | 1 | 2018 | 47 | 0.160 |
Why?
|
| Albumins | 2 | 2020 | 578 | 0.160 |
Why?
|
| Mucous Membrane | 4 | 2019 | 660 | 0.160 |
Why?
|
| Adaptation, Biological | 1 | 2019 | 147 | 0.160 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2018 | 423 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2019 | 1905 | 0.150 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 10273 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 548 | 0.150 |
Why?
|
| Models, Biological | 8 | 2019 | 9505 | 0.150 |
Why?
|
| Lymphatic Metastasis | 5 | 2017 | 2930 | 0.150 |
Why?
|
| Paired Box Transcription Factors | 2 | 2016 | 206 | 0.150 |
Why?
|
| Cytokines | 5 | 2023 | 7449 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 2525 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 2 | 2021 | 4417 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 213 | 0.150 |
Why?
|
| Phosphorylation | 11 | 2022 | 8332 | 0.140 |
Why?
|
| Neoplasm, Residual | 2 | 2024 | 1014 | 0.140 |
Why?
|
| RNA Stability | 1 | 2019 | 322 | 0.140 |
Why?
|
| Exosomes | 1 | 2022 | 429 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2020 | 1755 | 0.140 |
Why?
|
| Melanoma, Amelanotic | 1 | 2017 | 19 | 0.140 |
Why?
|
| Yttrium Radioisotopes | 1 | 2018 | 114 | 0.140 |
Why?
|
| Pulmonary Fibrosis | 1 | 2001 | 507 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2015 | 568 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2004 | 2229 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 127 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 873 | 0.140 |
Why?
|
| Glioma | 2 | 2022 | 3523 | 0.140 |
Why?
|
| Subretinal Fluid | 1 | 2016 | 25 | 0.130 |
Why?
|
| Oxidoreductases | 2 | 2016 | 412 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 5442 | 0.130 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2016 | 32 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 692 | 0.130 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2015 | 17 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2019 | 356 | 0.130 |
Why?
|
| Retinoblastoma Protein | 4 | 2014 | 673 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2020 | 1797 | 0.130 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 184 | 0.130 |
Why?
|
| Liver Neoplasms | 4 | 2018 | 4362 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2017 | 618 | 0.130 |
Why?
|
| Antigen Presentation | 2 | 2019 | 1251 | 0.130 |
Why?
|
| Hypopigmentation | 1 | 2015 | 43 | 0.130 |
Why?
|
| Calcium Channels | 1 | 2019 | 624 | 0.130 |
Why?
|
| Granzymes | 1 | 2017 | 279 | 0.130 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2016 | 111 | 0.120 |
Why?
|
| Keratoacanthoma | 2 | 2012 | 33 | 0.120 |
Why?
|
| Nuclear Proteins | 3 | 2020 | 5808 | 0.120 |
Why?
|
| Guanidines | 1 | 2016 | 194 | 0.120 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2015 | 179 | 0.120 |
Why?
|
| Risk Assessment | 11 | 2021 | 24311 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 395 | 0.120 |
Why?
|
| Janus Kinase 1 | 1 | 2015 | 108 | 0.120 |
Why?
|
| Dogs | 2 | 2018 | 3847 | 0.120 |
Why?
|
| Compassionate Use Trials | 1 | 2014 | 50 | 0.120 |
Why?
|
| NAD | 2 | 2016 | 618 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2013 | 185 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 6 | 2015 | 1608 | 0.120 |
Why?
|
| Fibronectins | 2 | 2015 | 725 | 0.120 |
Why?
|
| Drug Industry | 1 | 2021 | 793 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 2 | 2018 | 1129 | 0.120 |
Why?
|
| Cisplatin | 4 | 2017 | 1661 | 0.120 |
Why?
|
| Computational Biology | 2 | 2019 | 3546 | 0.120 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 109 | 0.120 |
Why?
|
| Amino Acid Substitution | 6 | 2015 | 1744 | 0.120 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2014 | 270 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2018 | 13030 | 0.120 |
Why?
|
| Fibroblasts | 3 | 2020 | 4180 | 0.120 |
Why?
|
| Lactams, Macrocyclic | 1 | 2016 | 318 | 0.120 |
Why?
|
| Drug Tolerance | 1 | 2016 | 367 | 0.120 |
Why?
|
| Sunlight | 2 | 2013 | 337 | 0.110 |
Why?
|
| Quinolines | 3 | 2017 | 769 | 0.110 |
Why?
|
| Fatigue | 2 | 2019 | 1556 | 0.110 |
Why?
|
| Autoimmunity | 1 | 2022 | 1361 | 0.110 |
Why?
|
| Patient Rights | 1 | 2014 | 127 | 0.110 |
Why?
|
| Salvage Therapy | 3 | 2020 | 1277 | 0.110 |
Why?
|
| Infection Control | 1 | 2021 | 985 | 0.110 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 104 | 0.110 |
Why?
|
| Cell Cycle Proteins | 5 | 2022 | 3463 | 0.110 |
Why?
|
| Valine | 5 | 2016 | 410 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 647 | 0.110 |
Why?
|
| Genome | 2 | 2022 | 1749 | 0.110 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2013 | 43 | 0.110 |
Why?
|
| Retrospective Studies | 21 | 2022 | 81834 | 0.110 |
Why?
|
| Tumor Burden | 5 | 2021 | 1909 | 0.110 |
Why?
|
| Thiazoles | 1 | 2021 | 1541 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2018 | 5803 | 0.110 |
Why?
|
| RNA, Small Interfering | 7 | 2016 | 3437 | 0.110 |
Why?
|
| Age Factors | 5 | 2019 | 18478 | 0.110 |
Why?
|
| Anilides | 2 | 2014 | 415 | 0.110 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 2232 | 0.110 |
Why?
|
| Pyridinium Compounds | 1 | 2013 | 81 | 0.110 |
Why?
|
| Nevus, Pigmented | 1 | 2015 | 225 | 0.110 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2013 | 74 | 0.110 |
Why?
|
| Telomerase | 1 | 2018 | 751 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 1339 | 0.100 |
Why?
|
| Nelfinavir | 2 | 2016 | 68 | 0.100 |
Why?
|
| Autophagy | 4 | 2018 | 1349 | 0.100 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2012 | 74 | 0.100 |
Why?
|
| Risk Factors | 15 | 2021 | 74915 | 0.100 |
Why?
|
| Prospective Studies | 14 | 2022 | 54914 | 0.100 |
Why?
|
| Karyopherins | 1 | 2013 | 134 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 18048 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 22365 | 0.100 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 3543 | 0.100 |
Why?
|
| Immunohistochemistry | 9 | 2017 | 11138 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 1891 | 0.100 |
Why?
|
| Carcinoma, Ductal | 1 | 2012 | 97 | 0.100 |
Why?
|
| Drug Approval | 2 | 2017 | 817 | 0.100 |
Why?
|
| Pruritus | 1 | 2015 | 380 | 0.100 |
Why?
|
| Receptors, CXCR4 | 1 | 2017 | 729 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 369 | 0.100 |
Why?
|
| GTPase-Activating Proteins | 1 | 2015 | 471 | 0.100 |
Why?
|
| Butadienes | 5 | 2011 | 107 | 0.100 |
Why?
|
| Lymph Nodes | 2 | 2014 | 3472 | 0.100 |
Why?
|
| Skin Ulcer | 1 | 2013 | 131 | 0.100 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 153 | 0.100 |
Why?
|
| Critical Pathways | 1 | 2015 | 476 | 0.100 |
Why?
|
| Down-Regulation | 5 | 2022 | 2944 | 0.100 |
Why?
|
| Mice, Knockout | 8 | 2019 | 14480 | 0.100 |
Why?
|
| Neurofibromin 1 | 3 | 2021 | 190 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2019 | 1818 | 0.090 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 3941 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 2434 | 0.090 |
Why?
|
| Adolescent | 12 | 2022 | 89168 | 0.090 |
Why?
|
| Gene Expression Profiling | 7 | 2019 | 9507 | 0.090 |
Why?
|
| Dextromethorphan | 1 | 2011 | 37 | 0.090 |
Why?
|
| HEK293 Cells | 5 | 2020 | 4294 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 661 | 0.090 |
Why?
|
| Mitotic Index | 1 | 2011 | 164 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2017 | 3805 | 0.090 |
Why?
|
| Mitosis | 2 | 2013 | 1191 | 0.090 |
Why?
|
| Reimbursement Mechanisms | 1 | 2016 | 677 | 0.090 |
Why?
|
| Radiopharmaceuticals | 2 | 2018 | 2731 | 0.090 |
Why?
|
| Farnesyltranstransferase | 1 | 2010 | 71 | 0.090 |
Why?
|
| Interleukin-2 | 5 | 2019 | 1894 | 0.090 |
Why?
|
| Mitochondria | 4 | 2022 | 3672 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2014 | 724 | 0.090 |
Why?
|
| Omeprazole | 1 | 2011 | 106 | 0.090 |
Why?
|
| Disease Models, Animal | 11 | 2019 | 18388 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2022 | 5620 | 0.090 |
Why?
|
| Craniotomy | 1 | 2015 | 748 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 2015 | 557 | 0.090 |
Why?
|
| Heparin | 1 | 2017 | 1636 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 1357 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 2331 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 1749 | 0.090 |
Why?
|
| Neoplasm Transplantation | 4 | 2017 | 2017 | 0.090 |
Why?
|
| Transcription Factors | 8 | 2018 | 12174 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2018 | 36840 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 1943 | 0.080 |
Why?
|
| DNA Repair | 1 | 2019 | 2051 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 6 | 2014 | 3637 | 0.080 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 954 | 0.080 |
Why?
|
| Spectrum Analysis | 1 | 2011 | 450 | 0.080 |
Why?
|
| Microsomes | 1 | 2009 | 252 | 0.080 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 770 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 119 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2017 | 2358 | 0.080 |
Why?
|
| Midazolam | 1 | 2011 | 267 | 0.080 |
Why?
|
| Cell Growth Processes | 4 | 2012 | 383 | 0.080 |
Why?
|
| Multiprotein Complexes | 2 | 2013 | 1112 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2019 | 1354 | 0.080 |
Why?
|
| Transfection | 4 | 2020 | 5767 | 0.080 |
Why?
|
| Antigens, Neoplasm | 5 | 2021 | 2003 | 0.080 |
Why?
|
| Up-Regulation | 5 | 2020 | 4138 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 369 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 2430 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 988 | 0.080 |
Why?
|
| Morpholines | 3 | 2008 | 583 | 0.080 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2012 | 306 | 0.080 |
Why?
|
| Smoking | 1 | 2005 | 9099 | 0.080 |
Why?
|
| Hypertension | 2 | 2006 | 8611 | 0.080 |
Why?
|
| Vomiting | 3 | 2020 | 655 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2018 | 1435 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 467 | 0.080 |
Why?
|
| Drug Interactions | 2 | 2011 | 1421 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 863 | 0.080 |
Why?
|
| Mutation, Missense | 5 | 2020 | 2594 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 15460 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 1969 | 0.070 |
Why?
|
| Cell Survival | 5 | 2017 | 5801 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2011 | 842 | 0.070 |
Why?
|
| Kinetics | 1 | 2015 | 6348 | 0.070 |
Why?
|
| Radiology | 1 | 2021 | 2118 | 0.070 |
Why?
|
| RNA, Messenger | 5 | 2024 | 12813 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 4362 | 0.070 |
Why?
|
| Organoids | 2 | 2024 | 749 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2014 | 1409 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 305 | 0.070 |
Why?
|
| Positron-Emission Tomography | 4 | 2017 | 6657 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2013 | 2048 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 2260 | 0.070 |
Why?
|
| Nitriles | 5 | 2011 | 984 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 2046 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2011 | 980 | 0.070 |
Why?
|
| Alternative Splicing | 1 | 2011 | 1094 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2785 | 0.070 |
Why?
|
| Endothelial Cells | 3 | 2016 | 3586 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 560 | 0.070 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 195 | 0.070 |
Why?
|
| Calcium | 1 | 2019 | 5793 | 0.070 |
Why?
|
| Proteomics | 5 | 2021 | 3901 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 7451 | 0.060 |
Why?
|
| Genotype | 6 | 2019 | 13047 | 0.060 |
Why?
|
| Teratoma | 1 | 2009 | 405 | 0.060 |
Why?
|
| Plasma Cells | 1 | 2009 | 598 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 3 | 2020 | 2003 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 3 | 2022 | 2039 | 0.060 |
Why?
|
| Stromal Cells | 3 | 2017 | 1335 | 0.060 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2005 | 78 | 0.060 |
Why?
|
| Glutamic Acid | 4 | 2016 | 1192 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2012 | 832 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2015 | 5042 | 0.060 |
Why?
|
| Polyglutamic Acid | 1 | 2005 | 47 | 0.060 |
Why?
|
| Base Sequence | 4 | 2019 | 12428 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2017 | 1986 | 0.060 |
Why?
|
| Drug Monitoring | 3 | 2017 | 964 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2017 | 440 | 0.060 |
Why?
|
| Activating Transcription Factor 4 | 2 | 2017 | 86 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 1484 | 0.060 |
Why?
|
| Proteins | 2 | 2018 | 6008 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2007 | 414 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 621 | 0.060 |
Why?
|
| RNA | 3 | 2022 | 2727 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2016 | 4421 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 712 | 0.060 |
Why?
|
| Sample Size | 1 | 2008 | 851 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2014 | 2819 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2010 | 1599 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 6527 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1727 | 0.060 |
Why?
|
| Glucose | 1 | 2016 | 4355 | 0.060 |
Why?
|
| Kidney | 1 | 2019 | 7064 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2012 | 1099 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 588 | 0.060 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 495 | 0.050 |
Why?
|
| Glycolysis | 2 | 2019 | 838 | 0.050 |
Why?
|
| Rats | 2 | 2018 | 23839 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2019 | 1869 | 0.050 |
Why?
|
| SOXE Transcription Factors | 1 | 2023 | 73 | 0.050 |
Why?
|
| HT29 Cells | 2 | 2015 | 192 | 0.050 |
Why?
|
| Culture Media, Conditioned | 2 | 2016 | 522 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2007 | 649 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2013 | 1960 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 2958 | 0.050 |
Why?
|
| Tumor Necrosis Factors | 1 | 2023 | 109 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 2863 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3116 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2020 | 1343 | 0.050 |
Why?
|
| Lactate Dehydrogenases | 1 | 2022 | 26 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 876 | 0.050 |
Why?
|
| Endoribonucleases | 1 | 2024 | 229 | 0.050 |
Why?
|
| Protein Binding | 5 | 2015 | 9376 | 0.050 |
Why?
|
| Massachusetts | 3 | 2021 | 8908 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Succinates | 1 | 2022 | 83 | 0.050 |
Why?
|
| Gene Expression | 4 | 2019 | 7605 | 0.050 |
Why?
|
| Research | 1 | 2011 | 1984 | 0.050 |
Why?
|
| Neoplasms, Experimental | 2 | 2017 | 1232 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2017 | 20762 | 0.050 |
Why?
|
| Receptors, Death Domain | 1 | 2022 | 31 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2023 | 190 | 0.050 |
Why?
|
| Doxycycline | 2 | 2015 | 348 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2008 | 1608 | 0.050 |
Why?
|
| Thrombocytopenia | 3 | 2005 | 1183 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 3826 | 0.050 |
Why?
|
| beta Catenin | 2 | 2017 | 1048 | 0.050 |
Why?
|
| Janus Kinases | 1 | 2023 | 253 | 0.050 |
Why?
|
| Autoantibodies | 2 | 2022 | 2131 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2001 | 119 | 0.050 |
Why?
|
| Protein Kinase C-alpha | 1 | 2001 | 113 | 0.050 |
Why?
|
| Taxoids | 1 | 2005 | 669 | 0.050 |
Why?
|
| Benchmarking | 1 | 2008 | 1058 | 0.050 |
Why?
|
| Inflammation | 2 | 2020 | 10865 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 11206 | 0.050 |
Why?
|
| Nucleosides | 1 | 2021 | 131 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2024 | 738 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2004 | 564 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2017 | 5904 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2009 | 1166 | 0.050 |
Why?
|
| Interdisciplinary Studies | 1 | 2021 | 86 | 0.040 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2020 | 60 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2014 | 3586 | 0.040 |
Why?
|
| Osteolysis | 1 | 2002 | 274 | 0.040 |
Why?
|
| Cohort Studies | 6 | 2024 | 41797 | 0.040 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2020 | 120 | 0.040 |
Why?
|
| Placebos | 2 | 2019 | 1668 | 0.040 |
Why?
|
| Mastocytosis | 1 | 2002 | 150 | 0.040 |
Why?
|
| Point Mutation | 2 | 2017 | 1596 | 0.040 |
Why?
|
| Liposomes | 1 | 2004 | 792 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2017 | 8730 | 0.040 |
Why?
|
| Forecasting | 1 | 2009 | 2950 | 0.040 |
Why?
|
| Tristetraprolin | 1 | 2019 | 40 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2021 | 361 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 2 | 2016 | 432 | 0.040 |
Why?
|
| Caspases | 1 | 2023 | 884 | 0.040 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 793 | 0.040 |
Why?
|
| Italy | 2 | 2012 | 853 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2015 | 1629 | 0.040 |
Why?
|
| Microfluidic Analytical Techniques | 2 | 2017 | 825 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2014 | 743 | 0.040 |
Why?
|
| Mutant Proteins | 2 | 2011 | 489 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 2659 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 473 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 6241 | 0.040 |
Why?
|
| Heparitin Sulfate | 1 | 2020 | 224 | 0.040 |
Why?
|
| Ligands | 2 | 2017 | 3281 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2005 | 716 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 2915 | 0.040 |
Why?
|
| Dermis | 1 | 2020 | 204 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2019 | 169 | 0.040 |
Why?
|
| Protein Isoforms | 2 | 2015 | 1706 | 0.040 |
Why?
|
| Wound Healing | 1 | 2010 | 2819 | 0.040 |
Why?
|
| Sarcoma | 1 | 2009 | 1806 | 0.040 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2018 | 72 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1998 | 108 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2019 | 311 | 0.040 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 12561 | 0.040 |
Why?
|
| PPAR alpha | 1 | 2019 | 177 | 0.040 |
Why?
|
| Mycoplasma hyorhinis | 1 | 2017 | 8 | 0.040 |
Why?
|
| Gammaproteobacteria | 1 | 2017 | 28 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 1669 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 2018 | 385 | 0.040 |
Why?
|
| Sulfones | 1 | 2020 | 448 | 0.040 |
Why?
|
| Algorithms | 2 | 2015 | 14158 | 0.040 |
Why?
|
| Adaptor Protein Complex sigma Subunits | 1 | 2017 | 10 | 0.040 |
Why?
|
| Infusions, Intravenous | 3 | 2010 | 2228 | 0.040 |
Why?
|
| Viremia | 1 | 2020 | 725 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2017 | 2491 | 0.040 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2017 | 58 | 0.040 |
Why?
|
| Caspase 9 | 1 | 2017 | 185 | 0.040 |
Why?
|
| Chromones | 2 | 2008 | 148 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 1379 | 0.030 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2017 | 71 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2021 | 1585 | 0.030 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 102 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 5510 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2001 | 1207 | 0.030 |
Why?
|
| Aging | 1 | 2016 | 8761 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 239 | 0.030 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2016 | 13 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2019 | 353 | 0.030 |
Why?
|
| Acetanilides | 1 | 2018 | 169 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2018 | 2656 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2017 | 329 | 0.030 |
Why?
|
| Arginine | 1 | 2020 | 923 | 0.030 |
Why?
|
| RNA Interference | 2 | 2016 | 2832 | 0.030 |
Why?
|
| Time-Lapse Imaging | 1 | 2017 | 195 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 12096 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2020 | 607 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2017 | 162 | 0.030 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1751 | 0.030 |
Why?
|
| Pentosyltransferases | 1 | 2015 | 62 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2017 | 413 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 262 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2016 | 160 | 0.030 |
Why?
|
| Apyrase | 1 | 2018 | 374 | 0.030 |
Why?
|
| Wnt1 Protein | 1 | 2016 | 123 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 1322 | 0.030 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2016 | 72 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2017 | 19041 | 0.030 |
Why?
|
| Workflow | 1 | 2021 | 861 | 0.030 |
Why?
|
| Nurses | 1 | 2005 | 2494 | 0.030 |
Why?
|
| Cellulitis | 1 | 2017 | 209 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2020 | 879 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2017 | 781 | 0.030 |
Why?
|
| G1 Phase | 2 | 2007 | 404 | 0.030 |
Why?
|
| Exons | 2 | 2011 | 2392 | 0.030 |
Why?
|
| Obesity | 1 | 2018 | 13065 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 213 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2017 | 595 | 0.030 |
Why?
|
| Integrin alpha5beta1 | 1 | 2015 | 36 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 295 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 663 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2016 | 287 | 0.030 |
Why?
|
| Cell Movement | 2 | 2019 | 5223 | 0.030 |
Why?
|
| Data Collection | 1 | 2024 | 3329 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 116 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2017 | 732 | 0.030 |
Why?
|
| Germ Cells | 1 | 2019 | 641 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 223 | 0.030 |
Why?
|
| Genes, APC | 1 | 2015 | 145 | 0.030 |
Why?
|
| Therapies, Investigational | 1 | 2015 | 111 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 9558 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 798 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2019 | 2298 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 2016 | 560 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 2360 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2016 | 228 | 0.030 |
Why?
|
| Benzocycloheptenes | 1 | 2014 | 7 | 0.030 |
Why?
|
| Brain | 2 | 2019 | 27438 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2015 | 323 | 0.030 |
Why?
|
| Scleroderma, Systemic | 1 | 1998 | 349 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2018 | 4029 | 0.030 |
Why?
|
| Epitopes | 1 | 2021 | 2526 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 14728 | 0.030 |
Why?
|
| Clobetasol | 1 | 2014 | 33 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 1376 | 0.030 |
Why?
|
| Glutarates | 1 | 2015 | 243 | 0.030 |
Why?
|
| Interleukins | 1 | 2019 | 792 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2017 | 705 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2014 | 139 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 1226 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2015 | 213 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 591 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 381 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2013 | 71 | 0.030 |
Why?
|
| Anemia | 1 | 2003 | 1521 | 0.030 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2015 | 244 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2013 | 147 | 0.030 |
Why?
|
| Indolizines | 1 | 2013 | 30 | 0.030 |
Why?
|
| Phylogeny | 1 | 2021 | 2846 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2017 | 1251 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 2013 | 72 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2013 | 67 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 20231 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 2173 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 1963 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2014 | 283 | 0.030 |
Why?
|
| Mohs Surgery | 1 | 2015 | 222 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1706 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 474 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 617 | 0.030 |
Why?
|
| Philadelphia | 1 | 2013 | 271 | 0.030 |
Why?
|
| Photosensitivity Disorders | 1 | 2012 | 79 | 0.030 |
Why?
|
| Warts | 1 | 2012 | 66 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1993 | 564 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 598 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2020 | 2865 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 5495 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 363 | 0.020 |
Why?
|
| Pandemics | 2 | 2023 | 8753 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2015 | 1650 | 0.020 |
Why?
|
| Oncogenes | 1 | 2017 | 1235 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2021 | 7599 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2001 | 1606 | 0.020 |
Why?
|
| Keratosis, Actinic | 1 | 2012 | 73 | 0.020 |
Why?
|
| Device Approval | 1 | 2013 | 164 | 0.020 |
Why?
|
| Telomere | 1 | 2018 | 943 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 716 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 1044 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1898 | 0.020 |
Why?
|
| Sex Factors | 1 | 2005 | 10647 | 0.020 |
Why?
|
| Transgenes | 1 | 2015 | 1015 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 998 | 0.020 |
Why?
|
| Half-Life | 1 | 2012 | 650 | 0.020 |
Why?
|
| Viral Load | 1 | 2020 | 3399 | 0.020 |
Why?
|
| Antibodies | 1 | 2019 | 2425 | 0.020 |
Why?
|
| Clone Cells | 1 | 2014 | 1672 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 1021 | 0.020 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 2544 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2014 | 616 | 0.020 |
Why?
|
| Aminolevulinic Acid | 1 | 2012 | 150 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2013 | 978 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 1139 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2010 | 69 | 0.020 |
Why?
|
| Program Development | 1 | 2017 | 1296 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2010 | 38 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2016 | 1086 | 0.020 |
Why?
|
| Diphenylamine | 1 | 2010 | 49 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 1905 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2010 | 63 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2020 | 3234 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2014 | 356 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 1644 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 105 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 979 | 0.020 |
Why?
|
| Cell Death | 1 | 2015 | 1684 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2018 | 1265 | 0.020 |
Why?
|
| Intestines | 1 | 2019 | 1912 | 0.020 |
Why?
|
| Cell Line | 2 | 2017 | 15609 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2013 | 504 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3438 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2013 | 1468 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 287 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 1514 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 2010 | 424 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 1998 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2017 | 1897 | 0.020 |
Why?
|
| Headache | 1 | 2017 | 1260 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 3212 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2006 | 4906 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 1026 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2016 | 2731 | 0.020 |
Why?
|
| Cell Communication | 1 | 2016 | 1662 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3854 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 2016 | 968 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2010 | 903 | 0.020 |
Why?
|
| Cell Separation | 1 | 2014 | 1726 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 2477 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 1315 | 0.020 |
Why?
|
| Australia | 1 | 2012 | 1264 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1998 | 1926 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 882 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 15965 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 551 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 2150 | 0.020 |
Why?
|
| Bacteria | 1 | 2019 | 2226 | 0.020 |
Why?
|
| Universities | 1 | 2013 | 1007 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 595 | 0.020 |
Why?
|
| Gene Library | 1 | 2010 | 1064 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 2204 | 0.020 |
Why?
|
| Boston | 1 | 2021 | 9361 | 0.020 |
Why?
|
| Nevus | 1 | 2009 | 206 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 3790 | 0.020 |
Why?
|
| Gadolinium | 1 | 2013 | 965 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2014 | 1276 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 1503 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1855 | 0.020 |
Why?
|
| Photosensitizing Agents | 1 | 2012 | 633 | 0.020 |
Why?
|
| Metformin | 1 | 2015 | 914 | 0.020 |
Why?
|
| G2 Phase | 1 | 2007 | 136 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15880 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2010 | 812 | 0.020 |
Why?
|
| Ruthenium | 1 | 2007 | 18 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 9623 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2015 | 1412 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2007 | 60 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 1196 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 319 | 0.020 |
Why?
|
| Anxiety | 1 | 2021 | 4655 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2007 | 406 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 1497 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2013 | 8081 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2016 | 3664 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2010 | 828 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 1775 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 1221 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2016 | 2714 | 0.020 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 58 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2932 | 0.020 |
Why?
|
| Metabolomics | 1 | 2015 | 1675 | 0.020 |
Why?
|
| Androstadienes | 1 | 2008 | 348 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 2461 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 499 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5308 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 4249 | 0.020 |
Why?
|
| Child | 3 | 2023 | 80863 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2014 | 1214 | 0.020 |
Why?
|
| Zebrafish | 1 | 2017 | 3038 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 882 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4586 | 0.020 |
Why?
|
| Leucovorin | 1 | 2007 | 643 | 0.020 |
Why?
|
| Family Health | 1 | 1990 | 1256 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 2987 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 3955 | 0.020 |
Why?
|
| China | 1 | 2011 | 2398 | 0.020 |
Why?
|
| Astrocytes | 1 | 2013 | 1354 | 0.010 |
Why?
|
| Demography | 1 | 2009 | 1643 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3145 | 0.010 |
Why?
|
| Flavonoids | 1 | 2008 | 447 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 1034 | 0.010 |
Why?
|
| Proteome | 1 | 2014 | 1881 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 4572 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2015 | 3577 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2901 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2013 | 2575 | 0.010 |
Why?
|
| Single-Cell Analysis | 1 | 2016 | 2531 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1143 | 0.010 |
Why?
|
| Models, Molecular | 2 | 2010 | 5443 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1795 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2012 | 1884 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 3048 | 0.010 |
Why?
|
| Stilbenes | 1 | 2005 | 155 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 14766 | 0.010 |
Why?
|
| Folic Acid Antagonists | 1 | 2004 | 75 | 0.010 |
Why?
|
| Camptothecin | 1 | 2007 | 594 | 0.010 |
Why?
|
| Immune System | 1 | 2009 | 801 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2001 | 5192 | 0.010 |
Why?
|
| Medicine | 1 | 2011 | 946 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2014 | 2757 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2006 | 943 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2012 | 1505 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 3111 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2007 | 1656 | 0.010 |
Why?
|
| Macrophages | 1 | 2017 | 5797 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 2826 | 0.010 |
Why?
|
| Health Status | 1 | 2015 | 4096 | 0.010 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2002 | 101 | 0.010 |
Why?
|
| Safety | 1 | 2006 | 1159 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1990 | 2203 | 0.010 |
Why?
|
| Registries | 1 | 2017 | 8373 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2007 | 1197 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 21552 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10845 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 4834 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 3108 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 17647 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2009 | 6353 | 0.010 |
Why?
|
| Cell Division | 1 | 2007 | 4479 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2009 | 4419 | 0.010 |
Why?
|
| Contrast Media | 1 | 2013 | 5336 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 16029 | 0.010 |
Why?
|
| Family | 1 | 1990 | 3208 | 0.010 |
Why?
|
| Consensus | 1 | 2009 | 3207 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 4941 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2016 | 11674 | 0.010 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 1998 | 94 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2013 | 9382 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3794 | 0.010 |
Why?
|
| Skin | 1 | 2011 | 4520 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 22293 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 6091 | 0.010 |
Why?
|
| Vital Capacity | 1 | 1998 | 984 | 0.010 |
Why?
|
| RNA Polymerase II | 1 | 1998 | 547 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1998 | 1820 | 0.010 |
Why?
|
| HIV-1 | 1 | 1990 | 6966 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 9066 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 7575 | 0.010 |
Why?
|
| Heart Failure | 1 | 2015 | 11857 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1993 | 1688 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15638 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1993 | 3073 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 11930 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1990 | 1604 | 0.000 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1990 | 530 | 0.000 |
Why?
|
| Binding Sites | 1 | 1993 | 6030 | 0.000 |
Why?
|
| HIV Seropositivity | 1 | 1990 | 963 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1990 | 2206 | 0.000 |
Why?
|
| HIV Antibodies | 1 | 1990 | 1341 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13452 | 0.000 |
Why?
|
| Sexual Behavior | 1 | 1990 | 2200 | 0.000 |
Why?
|